The markets extended its gains during the midday with the Dow surging 133 points to 18,174. Nasdaq soared 64 points to 5,097.
On the upside
Ceres (Nasdaq: CERE) received a U.S. patent for a genetic sequence derived from soybean.
Galena Biopharma (Nasdaq: GALE) announced that two abstracts published by American Society of Clinical Oncology advanced the company’s cancer immunotherapy programs NeuVax and GALE-301.
Retrophin (Nasdaq: RTRX) will sell its Rare Pediatric Disease Priority Review Voucher to Sanofi (NYSE: SNY).
On the downside
GlobeImmune (Nasdaq: GBIM) reported disappointing results from a Phase 2 study of GS-4774 to treat chronic hepatitis B.
Prima BioMed (Nasdaq: PBMD) partnered with Database Integrations to commercialize iCAN, the software platform powering Prima’s CVac cellular therapy, but the stock price fell.
Shares of Shake Shack (NYSE: SHAK) continued falling.
In the broad market, advancing issues outpaced decliners by a margin of 7 to 3 on the NYSE and by nearly 5 to 2 on Nasdaq. The broader S&P 500 soared 17 points to 2122. Bitcoin eased a fraction to $236.
